About INCRELEX®

INCRELEX® (mecasermin) injection is the first genetically engineered human insulin-like growth factor-1 (IGF-1) therapy used to treat children with Severe Primary IGF-1 Deficiency.

What is INCRELEX®?

What is INCRELEX®?

INCRELEX® is a liquid that contains man-made insulin-like growth factor-1 (IGF-1).
INCRELEX® works by replacing missing IGF-1 in the body.
INCRELEX® is used to treat children who are very short for their age because their bodies do not make enough IGF-1.
This condition is called primary IGF-1 deficiency.
IGF-1 should not be used instead of growth hormone.
It is not known if INCRELEX® is safe and effective in children under 2 years of age.

How INCRELEX® is thought to work

How INCRELEX® is thought to work

INCRELEX® replaces missing IGF-1 in the body which is a naturally occurring hormone that is essential for childhood growth.

Watch the video to find out how INCRELEX® is thought to work.

Warnings

Who should not receive INCRELEX®?

Your child should not receive INCRELEX® if your child:

  • is allergic to mecasermin or any of the ingredients in INCRELEX®;
  • has finished growing;
  • has any cancerous tumors or growths;
  • or has a history of cancer.

Your child should never receive INCRELEX® through a vein.

Talking to the doctor

What should I tell my child’s doctor before my child starts INCRELEX®?

Tell your child’s doctor about all of your child’s medical conditions, including if your child has diabetes; a curved spine (scoliosis); or is pregnant or breast-feeding.

Tell your child’s doctor about all the medicines (prescription and over-the-counter), vitamins, and herbal supplements your child takes. Especially tell your child’s doctor if your child takes insulin or other anti-diabetes medicines; a change in dose may be needed.

Side effects

What are possible side effects of INCRELEX®?

INCRELEX® may cause serious side effects, including:

Low blood sugar (hypoglycemia).

INCRELEX® may lower blood sugar levels. It is important to only give your child INCRELEX® 20 minutes before or 20 minutes after a meal or snack to reduce the chances of low blood sugar. Do not give your child INCRELEX® if your child cannot eat. Signs of low blood sugar include: dizziness; tiredness; restlessness; hunger; irritability; trouble concentrating; sweating; nausea; and fast or irregular heartbeat. Severe low blood sugar may cause unconsciousness, seizures, or death. Your child should avoid participating in high risk activities (e.g. driving, exercise, etc.) within 2 to 3 hours after the INCRELEX® injection, especially at the beginning of treatment. Your child should always have a source of sugar such as orange juice, glucose gel, candy, or milk available in case symptoms of low blood sugar happen. For severe low blood sugar, if your child is not responsive and cannot drink sugar-containing fluids, you should get emergency medical help for your child right away.

Allergic reactions

are a serious but common side effect of INCRELEX®. Call your child’s doctor right away if your child gets a rash or hives, which generally appear minutes to hours after the injection and may sometimes occur at many places on the skin. Stop taking INCRELEX® and get medical help right away if your child has trouble breathing or goes into shock, with symptoms like dizziness, pale, clammy skin or passing out. INCRELEX® can also cause reactions at the injection site including: loss of fat (lipoatrophy); increase of fat (lipohypertrophy); pain; redness; or bruising.

Increased pressure in the brain (intracranial hypertension).

INCRELEX®, like growth hormone, can sometimes cause a temporary increase in pressure within the brain. Symptoms include persistent headache and nausea with vomiting.

Enlarged tonsils.

Signs include: snoring, difficulty breathing, sleep apnea (a condition where breathing stops briefly during sleep), or fluid in the middle-ear.

A bone problem called slipped capital femoral epiphysis.

When the top of the upper leg bone (femur) slips apart. Get medical help for your child right away if your child develops a limp or has hip or knee pain.

Worsened scoliosis

(caused by rapid growth).

Tumor Growths.

Several cases of cancerous tumors have been observed in children who received INCRELEX®. Tell your doctor immediately if your child develops any new growths or symptoms of cancer.

Benzyl alcohol toxicity.

Benzyl alcohol, a preservative in INCRELEX®, can cause serious side effects, including death in infants.

The most common side effects of INCRELEX® include: Low blood sugar (hypoglycemia); injection site reactions; allergic reactions; and enlarged tonsils.

These are not all the side effects of INCRELEX®. Call your child’s doctor if your child has side effects that are bothersome or that do not go away. You may report side effects to FDA at 1​​-​​800​​-​​FDA​​-​​1088.

Receiving INCRELEX®

How Should my Child Receive INCRELEX®?

The dose of INCRELEX® to be given per injection can vary for each child. Your child’s doctor will determine the appropriate dose by taking into account your child’s weight, height, age, and other factors, such as tolerability. This information will be given to you, along with exact instructions and a dosing sheet.

A summary of how your child should receive INCRELEX® is given here. Detailed INCRELEX® injection instructions can be found in the Patient Information Leaflet and Instructions for Use.

Tips for Injecting INCRELEX®

Use Increlex Chart

 

*Adapted from the INCRELEX® Patient Information Leaflet

Dosing

What you should know about INCRELEX® dosing

Your child’s doctor will determine the correct dose of INCRELEX®. It is important that your child is weighed and measured regularly so their dose can be adjusted by their physician as appropriate. The starting dose of INCRELEX should be between 0.04 and 0.08 mg/kg. If a dose is well-tolerated for at least one week, then the doctor may choose to increase the dose by 0.04 mg/kg per dose, to the maximum dose of 0.12 mg/kg given twice daily. The dose should never be increased to make up for one or more skipped doses. INCRELEX® should not be administered when the meal or snack is skipped.

Because INCRELEX® has insulin-like hypoglycemic effects it should be administered shortly before or after (± 20 minutes) a meal or snack.

Children may show better growth results when their INCRELEX® dose is adjusted by their physician over the course of treatment. Regular weight monitoring is critical for proper dosing.

It is important that your child be weighed and measured regularly (e.g. monthly), so their dose can be adjusted as appropriate. You can keep your own records of your child’s growth, but it may be best to check in with the doctor’s office so you get the most accurate measurements.

INCRELEX® dosing for Severe Primary IGF-1 Deficiency treatment*

Dosing over 0.12 mg/kg twice daily may increase the potential for a hypoglycemic (low blood sugar) effect, and therefore higher than recommended dosing should not be used. Several cases of cancerous tumors have been observed in pediatric patients who received treatment with INCRELEX. The tumors were observed more frequently in patients who received INCRELEX at higher than recommended doses. Tell your doctor immediately if your child develops any new growths or symptoms of cancer.

 

INCRELEX® should be given 20 minutes before or after eating a snack or meal to reduce the chance of hypoglycemia. If your child is unable to eat shortly before or after a dose for any reason, that dose of INCRELEX® should not be given. If your child misses a dose, do not double a dose to make up for it.

INDICATION

INCRELEX® (mecasermin) is indicated for the treatment of growth failure in pediatric patients aged 2 years and older with severe primary IGF-1 deficiency* (IGFD), or with hormone (GH) gene deletion who have developed neutralizing antibodies to GH.

Limitations of use: INCRELEX is not a substitute to GH for approved GH indications. INCRELEX is not indicated for use in patients with secondary forms of IGFD, such as GH deficiency, malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.

*Severe primary IGF-1 deficiency (IGFD) is defined by height standard deviation score ≤ -3.0 and basal IGF-1 standard deviation score ≤ -3.0 and normal or elevated GH.

IMPORTANT SAFETY INFORMATION

Contraindications

  • Hypersensitivity: to mecasermin (rhIGF-1), any of the inactive ingredients in INCRELEX, or who have experienced a severe hypersensitivity to INCRELEX. Allergic reactions have been reported, including anaphylaxis requiring hospitalization.

Intravenous Administration

Closed Epiphyses

Malignant Neoplasia in pediatric patients with malignant neoplasia or a history of malignancy.

Warnings and Precautions

  • Hypoglycemia: INCRELEX should be administered 20 minutes before or after a meal or snack and should not be administered when the meal or snack is omitted. Glucose monitoring and INCRELEX dose titration are recommended until a well-tolerated dose is established and as medically indicated.
  • Intracranial Hypertension: Funduscopic examination is recommended at the initiation of and periodically during the course of therapy.
  • Lymphoid Tissue Hypertrophy: Patients should have periodic examinations to rule out potential complications.
  • Slipped Capital Femoral Epiphysis: Carefully evaluate any pediatric patient with the onset of a limp or hip/knee pain during INCRELEX therapy.
  • Progression of Scoliosis: Patients with a history of scoliosis, treated with INCRELEX, should be monitored.
  • Malignant Neoplasia: There have been postmarketing reports of malignant neoplasia in pediatric patients who received treatment with INCRELEX. The tumors were observed more frequently in patients who received INCRELEX at higher than recommended doses or at doses that produced serum IGF-1 levels above the normal reference ranges for age and sex. Monitor all patients receiving INCRELEX carefully for development of neoplasms. If malignant neoplasia develops, discontinue INCRELEX treatment.
  • Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preserved Solution: Serious and fatal adverse reactions including “gasping syndrome” can occur in neonates and infants treated with benzyl alcohol-preserved drugs. Use of INCRELEX in infants is not recommended.

Adverse Reactions

Common adverse reactions include hypoglycemia, local and systemic hypersensitivity, and tonsillar hypertrophy.

To report a suspected adverse event related to INCRELEX, contact Eton Pharmaceuticals, Inc. at 1-855-224-0233 or the U.S. Food and Drug Administration (FDA) at www.fda.gov/safety/Medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information for more information.